Arvinas, Inc. (ARVN) shareholders
Close on Nov 17, 2026Market cap $445.93MP/E 42.6Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 5,422,796 | 7.90% | 13G (passive) amendment | Mar 31, 2025 |
| Logos Global Management LP Joint filing with Logos Global Management GP LLC (6.40%), Arsani William (6.40%) | 4,800,000 | 6.40% | 13D (active) | Jun 9, 2025 |
| Vanguard Portfolio Management | 3,917,671 | 6.12% | 13G (passive) | Mar 31, 2026 |
| D. E. Shaw & Co., L.P. Joint filing with David E. Shaw (5.40%) | 3,495,153 | 5.40% | 13G (passive) amendment | Jun 30, 2026 |
| David E. Shaw Joint filing with D. E. Shaw & Co., L.P. (5.30%), D. E. Shaw & Co., L.L.C. (5.20%) | 3,405,026 | 5.30% | 13G (passive) | Nov 6, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARVN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,609,123 | 11.64% | $63.23M | +811,539 | 0.00% |
| Vanguard Portfolio Management LLC | 4,123,399 | 6.31% | $34.27M | +233,771 | 0.00% |
| D. E. Shaw & Co., Inc. | 3,495,153 | 5.35% | $29.04M | −143,414 | 0.01% |
| Pfizer Inc | 3,457,815 | 5.29% | $27.66M | – | 16.24% |
| Armistice Capital, LLC | 2,796,000 | 4.28% | $23.23M | +818,000 | 0.28% |
| Vanguard Capital Management LLC | 2,714,163 | 4.15% | $22.55M | +24,801 | 0.00% |
| Two Sigma Investments, LP | 2,573,447 | 3.94% | $21.39M | +741,333 | 0.02% |
| State Street Corp | 2,196,872 | 3.36% | $18.26M | +368,400 | 0.00% |
| Geode Capital Management, LLC | 1,667,265 | 2.55% | $13.86M | +110,158 | 0.00% |
| Qube Research & Technologies Ltd | 1,592,276 | 2.44% | $13.23M | +390,641 | 0.01% |
| Jacobs Levy Equity Management, Inc | 1,412,643 | 2.16% | $11.74M | −28,878 | 0.04% |
| Federated Hermes, Inc. | 1,356,032 | 2.07% | $11.27M | +215,317 | 0.02% |
| Nextech Invest, Ltd. | 1,122,713 | 1.72% | $17.12M | +583,319 | 0.81% |
| Acadian Asset Management LLC | 848,382 | 1.30% | $7.05M | −101,492 | 0.01% |
| Hillsdale Investment Management Inc. | 750,900 | 1.15% | $6.24M | New | 0.14% |
| Price T Rowe Associates Inc /Md/ | 728,147 | 1.11% | $6.05M | +301,054 | 0.00% |
| TCG Crossover Management, LLC | 707,098 | 1.08% | $5.88M | −1,680,363 | 0.14% |
| Dimensional Fund Advisors LP | 654,909 | 1.00% | $5.44M | +169,145 | 0.00% |
| Goldman Sachs Group Inc | 640,811 | 0.98% | $5.33M | −116,064 | 0.00% |
| Citadel Advisors LLC | 620,973 | 0.95% | $5.16M | −560,015 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 201 | 56M | 86.0% | 36 / 80 | 53 / 38 | 10M | 8M |
| Q1 2026 | 207 | 54M | 82.9% | 34 / 63 | 71 / 32 | 14M | 9M |
| Q4 2025 | 206 | 56M | 85.7% | 32 / 69 | 72 / 31 | 11M | 20M |
| Q3 2025 | 211 | 67M | 100.0% | 35 / 68 | 72 / 39 | 13M | 16M |
| Q2 2025 | 215 | 70M | 100.0% | 53 / 75 | 54 / 52 | 23M | 18M |
| Q1 2025 | 215 | 65M | 99.6% | 56 / 71 | 60 / 36 | 18M | 27M |
| Q4 2024 | 198 | 77M | 100.0% | 29 / 79 | 53 / 35 | 15M | 13M |
| Q3 2024 | 206 | 75M | 100.0% | 27 / 72 | 65 / 27 | 14M | 6M |
| Q2 2024 | 207 | 73M | 100.0% | 28 / 90 | 55 / 40 | 7M | 5M |
| Q1 2024 | 223 | 72M | 100.0% | 38 / 85 | 66 / 25 | 10M | 6M |
| Q4 2023 | 212 | 68M | 100.0% | 83 / 67 | 43 / 23 | 25M | 6M |
| Q3 2023 | 154 | 49M | 74.7% | 20 / 62 | 50 / 20 | 5M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
198 funds held ARVN in Q2 2026, 45% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ARVN | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,920,682 | 2.94% | $15.96M | 0.00% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 1,709,917 | 2.62% | $14.21M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,550,364 | 2.37% | $12.88M | 0.02% | Jun 30, 2026 |
| Vanguard Explorer Fund | 896,372 | 1.37% | $7.20M | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 727,428 | 1.11% | $6.04M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 648,842 | 0.99% | $5.21M | 0.02% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 642,928 | 0.98% | $5.34M | 1.25% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 561,301 | 0.86% | $4.51M | 0.20% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 529,728 | 0.81% | $4.76M | 0.09% | May 29, 2026 |
| iShares Russell 2000 Value ETF | 507,109 | 0.78% | $4.21M | 0.03% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 488,693 | 0.75% | $4.06M | 0.13% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 407,648 | 0.62% | $3.39M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 383,615 | 0.59% | $3.19M | 0.04% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 335,305 | 0.51% | $3.01M | 0.01% | May 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 322,526 | 0.49% | $2.68M | 0.05% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Randy Teel | President and CEO, Director | 285,009 | 0.44% | May 22, 2026 |
| David K. Loomis | VP, Chief Accounting Officer | 39,961 | 0.06% | Nov 9, 2026 |
| Andrew Saik | Chief Financial Officer | 187,432 | 0.29% | Jun 24, 2026 |
| Angela M. Cacace | Chief Scientific Officer | 180,390 | 0.28% | Jun 18, 2026 |
| Noah Berkowitz | Chief Medical Officer | 191,395 | 0.29% | May 13, 2026 |
| Ian Taylor | President, R&D | 160,785 | 0.25% | Feb 25, 2025 |
| Everett Cunningham | Director | 41,572 | 0.06% | Jun 26, 2026 |
| Briggs Morrison | Director | 111,548 | 0.17% | Jun 26, 2026 |
| Linda Bain | Director | 41,572 | 0.06% | Jun 26, 2026 |
| Edward Moore Kennedy Jr. | Director | 84,290 | 0.13% | Jun 26, 2026 |
| Leslie V. Norwalk | Director | 41,572 | 0.06% | Jun 26, 2026 |
| Alsup Laurie Smaldone | Director | 41,572 | 0.06% | Jun 26, 2026 |
| John G. Houston | Director | 1,122,183 | 1.72% | Mar 2, 2026 |
| Sunil Agarwal | Director | 30,166 | 0.05% | Jun 30, 2025 |
| John D. Young | Director | 26,045 | 0.04% | Jun 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David K. Loomis VP, Chief Accounting Officer | Nov 9, 2026 | Sale(10b5-1 plan) | −232 | $6.36 | $1.48K | 39,961 |
| Briggs Morrison Director | Jun 24, 2026 | Award | +15,527 | – | – | 111,548 |
| Leslie V. Norwalk Director | Jun 24, 2026 | Award | +15,527 | – | – | 41,572 |
| Linda Bain Director | Jun 24, 2026 | Award | +15,527 | – | – | 41,572 |
| Everett Cunningham Director | Jun 24, 2026 | Award | +15,527 | – | – | 41,572 |
| Edward Moore Kennedy Jr. Director | Jun 24, 2026 | Award | +15,527 | – | – | 54,957 |
| Alsup Laurie Smaldone Director | Jun 24, 2026 | Award | +15,527 | – | – | 41,572 |
| Andrew Saik Chief Financial Officer | Jun 24, 2026 | Sale(10b5-1 plan) | −5,696 | $8.16 | $46.48K | 187,432 |
| Angela M. Cacace Chief Scientific Officer | Jun 17, 2026 | Sale(10b5-1 plan) | −2,576 | $7.60 | $19.58K | 180,390 |
| Randy Teel President and CEO, Director | May 21, 2026 | Sale | −2,209 | $9.04 | $19.97K | 285,009 |
| David K. Loomis VP, Chief Accounting Officer | May 11, 2026 | Sale | −1,919 | $9.94 | $19.07K | 40,193 |
| Randy Teel President and CEO, Director | May 11, 2026 | Sale | −9,657 | $9.94 | $95.99K | 287,218 |
| Andrew Saik Chief Financial Officer | May 11, 2026 | Sale | −11,139 | $9.94 | $110.72K | 193,128 |
| Angela M. Cacace Chief Scientific Officer | May 11, 2026 | Sale | −9,657 | $9.94 | $95.99K | 182,966 |
| Noah Berkowitz Chief Medical Officer | May 11, 2026 | Sale | −11,108 | $9.94 | $110.41K | 191,395 |
| Noah Berkowitz Chief Medical Officer | Mar 18, 2026 | Sale | −6,435 | $11.10 | $71.43K | 202,503 |
| Briggs Morrison Director | Mar 6, 2026 | Buy | +20,000 | $13.40 | $268.00K | 96,021 |
| John G. Houston Director | Feb 27, 2026 | Sale | −11,787 | $13.14 | $154.88K | 1,122,183 |
| John G. Houston Director | Feb 27, 2026 | Sale | −18,822 | $13.24 | $249.20K | 1,133,970 |
| John G. Houston Director | Feb 27, 2026 | Sale | −4,688 | $13.24 | $62.07K | 1,152,792 |
| Randy Teel President and CEO, Director | Feb 26, 2026 | Award | +147,179 | – | – | 296,875 |
| Andrew Saik Chief Financial Officer | Feb 26, 2026 | Award | +45,000 | – | – | 204,267 |
| Angela M. Cacace Chief Scientific Officer | Feb 26, 2026 | Award | +45,000 | – | – | 192,623 |
| David K. Loomis VP, Chief Accounting Officer | Feb 26, 2026 | Award | +12,420 | – | – | 42,112 |
| Noah Berkowitz Chief Medical Officer | Feb 26, 2026 | Award | +45,000 | – | – | 208,938 |
| Randy Teel President and CEO, Director | Feb 26, 2026 | Award | +147,791 | – | – | 297,487 |
| Randy Teel President and CEO, Director | Feb 23, 2026 | Sale | −3,748 | $12.16 | $45.58K | 149,696 |
| Randy Teel President and CEO, Director | Feb 23, 2026 | Sale | −1,038 | $12.16 | $12.62K | 153,444 |
| David K. Loomis Chief Accounting Officer | Feb 23, 2026 | Sale | −1,108 | $12.16 | $13.47K | 29,692 |
| Angela M. Cacace Chief Scientific Officer | Feb 23, 2026 | Sale | −1,038 | $12.16 | $12.62K | 150,194 |
| Angela M. Cacace Chief Scientific Officer | Feb 23, 2026 | Sale | −2,571 | $12.16 | $31.26K | 147,623 |
| David K. Loomis Chief Accounting Officer | Feb 13, 2026 | Sale | −1,016 | $11.89 | $12.08K | 30,800 |
| Randy Teel President and CEO, Director | Feb 13, 2026 | Sale | −4,403 | $11.89 | $52.35K | 154,482 |
| Noah Berkowitz Chief Medical Officer | Feb 13, 2026 | Sale | −5,685 | $11.89 | $67.59K | 163,938 |
| Andrew Saik Chief Financial Officer | Feb 13, 2026 | Sale | −5,134 | $11.89 | $61.04K | 159,267 |
| Angela M. Cacace Chief Scientific Officer | Feb 13, 2026 | Sale | −4,592 | $11.89 | $54.60K | 151,232 |
| David K. Loomis Chief Accounting Officer | Nov 7, 2025 | Sale | −230 | $9.89 | $2.27K | 31,697 |
| Briggs Morrison Director | Sep 22, 2025 | Buy | +30,000 | $7.57 | $227.10K | 76,021 |
| Sunil Agarwal Director | Jun 25, 2025 | Award | +16,025 | – | – | 30,166 |
| Alsup Laurie Smaldone Director | Jun 25, 2025 | Award | +16,025 | – | – | 26,045 |
| Linda Bain Director | Jun 25, 2025 | Award | +16,025 | – | – | 26,045 |
| Edward Moore Kennedy Jr. Director | Jun 25, 2025 | Award | +16,025 | – | – | 39,430 |
| Leslie V. Norwalk Director | Jun 25, 2025 | Award | +16,025 | – | – | 26,045 |
| John D. Young Director | Jun 25, 2025 | Award | +16,025 | – | – | 26,045 |
| Briggs Morrison Director | Jun 25, 2025 | Award | +16,025 | – | – | 46,021 |
| Everett Cunningham Director | Jun 25, 2025 | Award | +16,025 | – | – | 26,045 |
| Andrew Saik Chief Financial Officer | Jun 24, 2025 | Sale | −5,700 | $7.61 | $43.38K | 164,401 |
| Angela M. Cacace Chief Scientific Officer | Jun 17, 2025 | Sale | −2,583 | $7.49 | $19.35K | 154,248 |
| Noah Berkowitz Chief Medical Officer | May 9, 2025 | Award | +59,600 | – | – | 169,623 |
| Angela M. Cacace Chief Scientific Officer | May 9, 2025 | Award | +59,600 | – | – | 156,831 |
| David K. Loomis Chief Accounting Officer | May 9, 2025 | Award | +11,825 | – | – | 30,688 |
| Andrew Saik Chief Financial Officer | May 9, 2025 | Award | +59,600 | – | – | 170,101 |
| Noah Berkowitz Chief Medical Officer | Mar 18, 2025 | Sale | −8,658 | $8.59 | $74.37K | 110,023 |
| Angela M. Cacace Chief Scientific Officer | Feb 24, 2025 | Sale | −3,061 | $16.75 | $51.27K | 98,377 |
| Angela M. Cacace Chief Scientific Officer | Feb 24, 2025 | Sale | −1,146 | $16.55 | $18.97K | 97,231 |
| John G. Houston President and CEO, Director | Feb 24, 2025 | Sale | −5,154 | $16.55 | $85.30K | 1,157,480 |
| John G. Houston President and CEO, Director | Feb 24, 2025 | Sale | −26,184 | $16.75 | $438.58K | 1,162,634 |
| David K. Loomis Chief Accounting Officer | Feb 24, 2025 | Sale | −1,214 | $16.75 | $20.33K | 18,863 |
| Ian Taylor President, R&D | Feb 24, 2025 | Sale | −7,356 | $16.75 | $123.21K | 160,785 |
| Ian Taylor President, R&D | Feb 24, 2025 | Sale | −1,664 | $16.55 | $27.54K | 159,121 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arvinas's stock actually held short. Settlement fails (shares not delivered on time) peaked at 688 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Sunil Agarwal Director | Sep 22, 2026 | 23,105 | $196.24K | Sep 22, 2026 | Stock Option Exercise |
| Noah Berkowitz Former Officer | Sep 9, 2026 | 37,200 | $328.91K | Sep 9, 2026 | Exercise of Options Under a Registered Plan |
| Noah Berkowitz Former Officer | Sep 4, 2026 | 8,300 | $78.44K | Sep 4, 2026 | Exercise of Options Under a Registered Plan |
| Noah Berkowitz Officer | Aug 4, 2026 | 30,000 | $264.00K | Aug 4, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Noah Berkowitz Former Affiliate | Jul 9, 2026 | 24,000 | $201.53K | Jul 9, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Andrew Saik Officer | Jun 23, 2026 | 5,846 | $47.59K | Jun 24, 2026 | Settlement of vested restricted stock units |
| Angela M. Cacace Officer | Jun 17, 2026 | 2,642 | $19.60K | Jun 17, 2026 | Settlement of vested restricted stock units |
| Randy Teel Officer, Director | May 20, 2026 | 2,197 | $19.99K | May 21, 2026 | Settlement of vested restricted stock units |
| Randy Teel Officer, Director | May 8, 2026 | 9,834 | $99.42K | May 11, 2026 | Settlement of vested restricted stock units |
| Angela M. Cacace Officer | May 8, 2026 | 9,834 | $99.42K | May 11, 2026 | Settlement of vested restricted stock units |
| Noah Berkowitz Officer | May 8, 2026 | 11,312 | $114.36K | May 11, 2026 | Settlement of vested restricted stock units |
| Andrew Saik Officer | May 8, 2026 | 11,343 | $114.68K | May 11, 2026 | Settlement of vested restricted stock units |
| Noah Berkowitz Officer | Mar 17, 2026 | 6,022 | $72.32K | Mar 18, 2026 | Settlement of vested restricted stock units |
| John G. Houston former President and CEO, Director | Feb 27, 2026 | 35,297 | $466.18K | Feb 27, 2026 | Settlement of vested restricted stock units |
| Angela M. Cacace Officer | Feb 23, 2026 | 3,609 | $43.90K | Feb 23, 2026 | Settlement of vested restricted stock units |
See a number that looks wrong?